Status:
COMPLETED
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Medarex
Conditions:
Melanoma
Eligibility:
All Genders
16+ years
Phase:
PHASE2
Brief Summary
The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, S...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma
Exclusion
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT00289640
Start Date
April 1 2006
End Date
July 1 2007
Last Update
March 2 2010
Active Locations (62)
Enter a location and click search to find clinical trials sorted by distance.
1
Arizona Cancer Center
Tucson, Arizona, United States, 85724
2
Wilshire Oncology Medical Group Inc
Laverne, California, United States, 91750
3
Scripps Cancer Center
San Diego, California, United States, 92121
4
The Angeles Clinic And Research Institution
Santa Monica, California, United States, 90404